Drug Discovery
By
Is Lilly Strengthening Its 2026 Growth Outlook by Scaling Zepbound, Mounjaro, and Its Core Innovation Engine in 2025?
In 2025, Eli Lilly and Company continued to build on its strong momentum, executing a focused strategy centered…
Pfizer’s Strategic Deals in 2025: Key Moves Shaping the Company’s Next Phase
Strategic Takeaways In 2025, Pfizer executed a series of focused and strategic deals aimed at strengthening its pipeline,…
Can Pfizer’s 2025 Execution Set the Stage for Sustainable Growth in 2026?
NEW YORK, NY — As 2025 comes to a close, Pfizer Inc. reflects on a year marked by…
Will the US Health Agency Expand Coverage for GLP-1 Weight-Loss Drugs?
The U.S. Centers for Medicare & Medicaid Services (CMS) announced a new voluntary program to expand coverage of…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026 and Beyond?
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
